These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34436623)
1. General Burden of Adult Atopic Dermatitis: An Observational Study of Disease Perceptions among Patients and Dermatologists in France. Soria A; Thénié C; Bienenfeld C; Staumont-Sallé D Acta Derm Venereol; 2021 Nov; 101(11):adv00588. PubMed ID: 34436623 [TBL] [Abstract][Full Text] [Related]
2. The caseload, assessment and treatment of atopic dermatitis: a survey of Australian dermatologists. Stephens RB; Cooper A Australas J Dermatol; 1999 Nov; 40(4):187-9. PubMed ID: 10570552 [TBL] [Abstract][Full Text] [Related]
3. Who sees you matters: a population study examining topical corticosteroid prescribing patterns between primary care providers and dermatologists for atopic dermatitis. Singh I; Chat VS; Uy A; Borba A; Chen AY; Armstrong AW J Dermatolog Treat; 2022 May; 33(3):1507-1510. PubMed ID: 33043730 [TBL] [Abstract][Full Text] [Related]
4. Impact of comorbidities on the treatment of atopic dermatitis in clinical practice. Werner-Busse A; Kostev K; Heine G; Worm M Int J Clin Pharmacol Ther; 2014 Sep; 52(9):726-31. PubMed ID: 25066227 [TBL] [Abstract][Full Text] [Related]
5. Agreement Between Self-reported and Dermatologists' Diagnosis for Alopecia Areata and Atopic Dermatitis: A Bi-centric Prospective Study. Richard MA; Ezzedine K Acta Derm Venereol; 2019 May; 99(6):618-619. PubMed ID: 30723873 [No Abstract] [Full Text] [Related]
6. Optimizing pharmaceutical care for pediatric patients with dermatitis: perspectives of parents and pharmacy staff. Koster ES; Philbert D; Wagelaar KR; Galle S; Bouvy ML Int J Clin Pharm; 2019 Jun; 41(3):711-718. PubMed ID: 31020600 [TBL] [Abstract][Full Text] [Related]
7. Quality of life of parents living with a child suffering from atopic dermatitis before and after a 3-month treatment with an emollient. Gelmetti C; Boralevi F; Seité S; Grimalt R; Humbert P; Luger T; Stalder JF; Taïeb A; Tennstedt D; Garcia Diaz R; Rougier A Pediatr Dermatol; 2012; 29(6):714-8. PubMed ID: 23106672 [TBL] [Abstract][Full Text] [Related]
8. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden. Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Tajima Y; Ardeleanu M; Rizova E; Arima K; J Dermatol; 2019 Apr; 46(4):290-300. PubMed ID: 30756423 [TBL] [Abstract][Full Text] [Related]
9. Focus group parental opinions regarding treatment with topical corticosteroids on children with atopic dermatitis. Veenje S; Osinga H; Antonescu I; Bos B; de Vries TW Allergol Immunopathol (Madr); 2019; 47(2):166-171. PubMed ID: 30316560 [TBL] [Abstract][Full Text] [Related]
10. Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists. Herranz-Pinto P; Figueras Nart I; Monte-Boquet E; Tortajada Goitia B Actas Dermosifiliogr; 2023 Sep; 114(8):708-717. PubMed ID: 37088291 [TBL] [Abstract][Full Text] [Related]
11. Physicians' perceptions of an eczema action plan for atopic dermatitis. Ntuen E; Taylor SL; Kinney M; O'Neill JL; Krowchuk DP; Feldman SR J Dermatolog Treat; 2010 Jan; 21(1):28-33. PubMed ID: 19968578 [TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Augustin M; Costanzo A; Pink A; Seneschal J; Schuster C; Mert C; Guerreiro M; Tietz N; Grond S; De Bruin-Weller M Acta Derm Venereol; 2022 Dec; 102():adv00830. PubMed ID: 36479885 [TBL] [Abstract][Full Text] [Related]
13. Atopic dermatitis: impact on quality of life and patients' attitudes toward its management. Torrelo A; Ortiz J; Alomar A; Ros S; Prieto M; Cuervo J Eur J Dermatol; 2012; 22(1):97-105. PubMed ID: 22237114 [TBL] [Abstract][Full Text] [Related]
14. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Aubert-Wastiaux H; Moret L; Le Rhun A; Fontenoy AM; Nguyen JM; Leux C; Misery L; Young P; Chastaing M; Danou N; Lombrail P; Boralevi F; Lacour JP; Mazereeuw-Hautier J; Stalder JF; Barbarot S Br J Dermatol; 2011 Oct; 165(4):808-14. PubMed ID: 21671892 [TBL] [Abstract][Full Text] [Related]
15. Agreement between dermatologists' selection of the lesional area and characteristics best representing atopic dermatitis severity: Online survey. Ali Z; Andersen AD; Bjerre-Christensen T; Zibert JR; Thomsen SF J Am Acad Dermatol; 2021 May; 84(5):e241-e242. PubMed ID: 33359591 [No Abstract] [Full Text] [Related]
16. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life]. Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059 [TBL] [Abstract][Full Text] [Related]
17. Review of Atopic Dermatitis and Topical Therapies. Mayba JN; Gooderham MJ J Cutan Med Surg; 2017; 21(3):227-236. PubMed ID: 28300440 [TBL] [Abstract][Full Text] [Related]
18. The knowledge of issues associated with topical corticosteroids using in patients with atopic dermatitis. Jaworek A; Szafraniec K; Pastuszczak M; Zalewski A; Wojas-Pelc A Pol Merkur Lekarski; 2019 Jun; 46(276):243-247. PubMed ID: 31260432 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009 [TBL] [Abstract][Full Text] [Related]
20. The economics of topical immunomodulators for the treatment of atopic dermatitis. Abramovits W; Boguniewicz M; Paller AS; Whitaker-Worth DL; Prendergast MM; Tokar M; Tong KB Pharmacoeconomics; 2005; 23(6):543-66. PubMed ID: 15960552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]